Stockhub

ChemoCentryx, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

19 August 2022

12 August 2022

5 August 2022

  • curprev 16:5016:50, 5 August 2022 >Paris 1,100 bytes +1,100 Created page with "ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hid..."
Retrieved from "https://stockhub.co/research/ChemoCentryx,_Inc."